Pfizer Inc. (Pfizer) operates as a research-based, global biopharmaceutical company.
The company applies science and its global resources to bring therapies to people that extend, and significantly improve their lives, through the discovery, develop…
Analysis
Bargain bin
Pfizer Inc. falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause.
The price is attractive. You pay 12.9× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly 0% yearly growth; analysts expect -3%. The price, in other words, assumes less than the experts do.
The trajectory is weak and the balance sheet is stretched. The company scores 14/20 on our value-creation score: strong value creator.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202386
42
2023202420252026
All-time high
86
Jan 2025
All-time low
34
Dec 2025
Average rank
60
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
81
47
37
46
Price/Earnings
25
76
68
93
Price/Book
76
54
50
31
Dividend Yield
100
100
100
100
Value (overall)
98
96
99
98
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.